Ypsomed Holding AG (0QLQ) Q2 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Ypsomed Holding Ag.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:03.833 to Ipsomed Half Year Results 2025-2026 00:00:04.855 -- 00:00:07.297 Earnings Conference Call. 00:00:07.297 -- 00:00:12.482 Today, with CEO Simon Michel and CFO 00:00:12.482 -- 00:00:18.447 Samuel Künzli, we'd like to go over our first half year results. 00:00:18.447 -- 00:00:23.492 We'll go over the key achievements and the financial drivers 00:00:23.492 -- 00:00:28.756 for this first half year. After a short presentation, we will open the floor 00:00:28.756 -- 00:00:30.085 to questions. 00:00:30.085 -- 00:00:35.195 thank you for for joining us again and a warm welcome to all without further ado i'll 00:00:35.195 -- 00:00:40.304 pass on then to simon please thank you very much sam for introduction uh good morning 00:00:40.304 -- 00:00:44.693 everybody great to take the time uh for us here this morning we have a great results 00:00:44.693 -- 00:00:49.381 you have seen it this morning let us deepen it i will do a channel overview and then 00:00:49.381 -- 00:00:53.546 hand over to samuel for the financials 00:00:53.828 -- 00:00:56.372 And as you know me, I always start with our purpose. 00:00:56.372 -- 00:01:01.380 This is why we get up every morning. IpsiMed is making self-care simpler and 00:01:01.380 -- 00:01:05.467 easier. And those four are our structural growth drivers. 00:01:05.467 -- 00:01:08.953 Therapy, go home, drugs have to be injected. 00:01:08.953 -- 00:01:14.301 More and more biosimilars are available. And the new large new class of GLP-1 00:01:14.301 -- 00:01:18.348 incretins that is giving IpsiMed a strong push. 00:01:18.348 -- 00:01:22.455 So we profit a lot. We have a lot of tailwind 00:01:22.455 -- 00:01:27.504 that supports Ipsumet in its growth. And we are really well set up. 00:01:27.504 -- 00:01:30.168 Ipsumet ...